MiNK Therapeutics, Inc.
INKT
$11.90
$0.453.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.96% | 65.79% | 56.00% | 1.42% | -19.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -145.30% | -102.80% | -102.80% | 367.50% | -- |
| Total Operating Expenses | 9.25% | 30.56% | 12.19% | -13.07% | -37.14% |
| Operating Income | -9.25% | -30.56% | -12.19% | 13.07% | 37.14% |
| Income Before Tax | -0.76% | -28.05% | -15.85% | 10.34% | 34.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.76% | -28.05% | -15.85% | 10.34% | 34.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.76% | -28.05% | -15.85% | 10.34% | 34.03% |
| EBIT | -9.25% | -30.56% | -12.19% | 13.07% | 37.14% |
| EBITDA | -10.01% | -31.71% | -12.74% | 13.14% | 37.64% |
| EPS Basic | 15.56% | -13.42% | -2.05% | 21.48% | 41.90% |
| Normalized Basic EPS | 14.27% | -15.18% | -0.44% | 22.67% | 42.82% |
| EPS Diluted | 15.56% | -13.42% | -2.05% | 21.48% | 41.90% |
| Normalized Diluted EPS | 14.27% | -15.18% | -0.44% | 22.67% | 42.82% |
| Average Basic Shares Outstanding | 19.51% | 14.88% | 13.17% | 12.06% | 12.59% |
| Average Diluted Shares Outstanding | 19.51% | 14.88% | 13.17% | 12.06% | 12.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |